Figure 3. Postoperative Minimal Residual Disease detection in early-stage NSCLC.

A-D. Longitudinal ctDNA data from non-pilot patients with (A) no evidence of non-small-cell lung cancer (NSCLC) recurrence, n=42; (B) development of a second-primary cancer, n=19; (C) recurrence of NSCLC in landmark positive patients, n=25 patients (D) recurrence of NSCLC in landmark negative patients, n=26 patients and (E) recurrence of NSCLC in landmark unevaluable patients, n=19 patients. In all panels, each circle represents a cfDNA sampling time point. Circles to the left of surgical day are preoperative timepoints, circles to the right of surgical day are postoperative timepoints. Black filled circle: positive ctDNA detection. Light blue rectangles: chemotherapy, dark blue rectangles: radiotherapy, orange rectangles: patient received post-recurrence surgery. Triangles represent standard of care postoperative CT, PET or MRI surveillance imaging (imaging up until first relapse or last follow-up displayed on plot). Imaging classified as no disease (grey), equivocal images (yellow), or unequivocal imaging evidence of extracranial relapse (red). Light green triangles: no evidence of intracranial relapse, dark green triangles: intracranial relapse. Vertical black lines: the event date for a patient (if death, second-primary, NSCLC recurrence occurred); otherwise, the vertical line represents last TRACERx follow-up. Crosses: patient death events. To the left of the panels, the annotation plots highlight histology, pTNM (pathological TNM) status, relapse site, and details regarding whether an intracranial relapse was isolated (brain-only) or non-isolated (brain and extracranial site) or occurred without extracranial imaging to confirm solitary status. Relapse site annotation displays anatomical sites of disease identified within an 180 day post-recurrence period.